First Time Loading...

Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 9.01 USD 2.15% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. [ Read More ]

The intrinsic value of one TBPH stock under the Base Case scenario is 14.41 USD. Compared to the current market price of 9.01 USD, Theravance Biopharma Inc is Undervalued by 37%.

Key Points:
TBPH Intrinsic Value
Base Case
14.41 USD
Undervaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Theravance Biopharma Inc

Backtest TBPH Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TBPH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Theravance Biopharma Signals Growth and Profits
2023-Q4 Earnings Call

Theravance Biopharma Signals Growth and Profits

Theravance Biopharma reported a productive 2023, increasing YUPELRI net sales 9% to $221 million and growing hospital volumes 46%. The company achieved non-GAAP profitability in Q4 and completed a $325 million capital return program. They are on track with the CYPRESS study for ampreloxetine and expect regulatory submission in China for YUPELRI midyear, aiming for greater market share. For 2024, a non-GAAP loss is anticipated in H1 due to seasonal drops in sales and increased R&D spend, with a return to breakeven expected in H2. A $25 million or $50 million TRELEGY milestone is possible, and limited cash burn is projected, with significant milestones anticipated to generate net cash before CYPRESS results in 2025.

Financials

Balance Sheet Decomposition
Theravance Biopharma Inc

Current Assets 133.5m
Cash & Short-Term Investments 102.4m
Receivables 17.5m
Other Current Assets 13.6m
Non-Current Assets 248.5m
PP&E 45.4m
Other Non-Current Assets 203.1m
Current Liabilities 24.8m
Other Current Liabilities 24.8m
Non-Current Liabilities 144.2m
Other Non-Current Liabilities 144.2m
Efficiency

Earnings Waterfall
Theravance Biopharma Inc

Revenue
57.4m USD
Operating Expenses
-110.7m USD
Operating Income
-53.3m USD
Other Expenses
-1.9m USD
Net Income
-55.2m USD

Free Cash Flow Analysis
Theravance Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TBPH Profitability Score
Profitability Due Diligence

Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Negative Net Income
Exceptional Revenue Growth Forecast
ROIC is Increasing
42/100
Profitability
Score

Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

TBPH Solvency Score
Solvency Due Diligence

Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
63/100
Solvency
Score

Theravance Biopharma Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TBPH Price Targets Summary
Theravance Biopharma Inc

Wall Street analysts forecast TBPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TBPH is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

Lowest
Price Target
10.1 USD
12% Upside
Average
Price Target
14.28 USD
58% Upside
Highest
Price Target
21 USD
133% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TBPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TBPH Price
Theravance Biopharma Inc

1M 1M
-4%
6M 6M
+8%
1Y 1Y
-15%
3Y 3Y
-56%
5Y 5Y
-61%
10Y 10Y
-61%
Annual Price Range
9.01
52w Low
8.22
52w High
11.92
Price Metrics
Average Annual Return -15.39%
Standard Deviation of Annual Returns 17.94%
Max Drawdown -78%
Shares Statistics
Market Capitalization 448.7m USD
Shares Outstanding 48 164 700
Percentage of Shares Shorted 42.77%

TBPH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Theravance Biopharma Inc Logo
Theravance Biopharma Inc

Country

Cayman Islands

Industry

Pharmaceuticals

Market Cap

448.7m USD

Dividend Yield

0%

Description

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

Contact

GRAND CAYMAN
GEORGE TOWN
Ugland House, South Church Street
+6508086000.0

IPO

2014-05-16

Employees

158

Officers

Chairman & CEO
Mr. Rick E. Winningham M.B.A.
Chief Business Officer and Senior VP of Commercial & Medical Affairs
Ms. Rhonda F. Farnum
Strategic Advisor
Dr. Richard A. Graham Ph.D.
Senior VP & CFO
Mr. Aziz Sawaf C.F.A.
VP of IT&I & Chief Information Officer
Stuart Knight
Vice President of Corporate Communications & Investor Relations
Ms. Gail B. Cohen
Show More
Senior VP, General Counsel & Secretary
Mr. Brett A. Grimaud Esq.
Senior VP & Chief Strategy Officer
Ms. Stacy L. Pryce
SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office
Dr. Aine Miller Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TBPH stock?

The intrinsic value of one TBPH stock under the Base Case scenario is 14.41 USD.

Is TBPH stock undervalued or overvalued?

Compared to the current market price of 9.01 USD, Theravance Biopharma Inc is Undervalued by 37%.